Jeffrey R. Moore, PhD
Adjunct Associate Professor, Pharmacology, Physiology & Biophysics
Biography
Our lab’s main interest is the study of molecular mechanics and cellular motility. We employ single molecule fluorescence techniques and laser trapping assays to study: the mechanism and regulation muscle contraction, cell motility, and the regulation of cell shape. Our lab’s investigations of cardiac muscle contraction focus on the effects of cardiomyopathy-causing amino acid substitutions on myosin’s mechanical and enzymatic properties. We are also investigating the nature and regulation of cytoskeletal dynamics in differentiated vascular smooth muscle cells.
Websites
Education
- University of Vermont, PhD
- University of Massachusetts Lowell, MS
- University of Massachusetts Lowell, BS
Publications
- Published on 12/16/2024
Halder SS, Rynkiewicz MJ, Kim L, Barry ME, Zied AG, Sewanan LR, Kirk JA, Moore JR, Lehman WJ, Campbell SG. Distinct mechanisms drive divergent phenotypes in hypertrophic and dilated cardiomyopathy-associated TPM1 variants. J Clin Invest. 2024 Dec 16; 134(24). PMID: 39436707.
Read at: PubMed - Published on 8/30/2024
Creso JG, Gokhan I, Rynkiewicz MJ, Lehman W, Moore JR, Campbell SG. In silico and in vitro models reveal the molecular mechanisms of hypocontractility caused by TPM1 M8R. Front Physiol. 2024; 15:1452509. PMID: 39282088.
Read at: PubMed - Published on 1/22/2024
Barry ME, Rynkiewicz MJ, Pavadai E, Viana A, Lehman W, Moore JR. Glutamate 139 of tropomyosin is critical for cardiac thin filament blocked-state stabilization. J Mol Cell Cardiol. 2024 Mar; 188:30-37. PMID: 38266978.
Read at: PubMed - Published on 1/21/2023
Halder SS, Rynkiewicz MJ, Creso JG, Sewanan LR, Howland L, Moore JR, Lehman W, Campbell SG. Mechanisms of pathogenicity in the hypertrophic cardiomyopathy-associated TPM1 variant S215L. PNAS Nexus. 2023 Mar; 2(3):pgad011. PMID: 36896133.
Read at: PubMed - Published on 1/12/2023
Doran MH, Rynkiewicz MJ, Rassici D, Bodt SML, Barry ME, Bullitt E, Yengo CM, Moore JR, Lehman W. Conformational changes linked to ADP release from human cardiac myosin bound to actin-tropomyosin. J Gen Physiol. 2023 Mar 06; 155(3). PMID: 36633586.
Read at: PubMed - Published on 12/2/2022
Doran MH, Rynkiewicz MJ, Pavadai E, Bodt SML, Rasicci D, Moore JR, Yengo CM, Bullitt E, Lehman W. Myosin loop-4 is critical for optimal tropomyosin repositioning on actin during muscle activation and relaxation. J Gen Physiol. 2023 Feb 06; 155(2). PMID: 36459134.
Read at: PubMed - Published on 11/29/2022
Campbell SG, Moore JR, Rynkiewicz MJ, Lehman W. Multi-scale modeling will unravel connections between sarcomeric mutations and cardiomyopathies. J Mol Cell Cardiol Plus. 2023 Mar; 3:100025. PMID: 39803360.
Read at: PubMed - Published on 7/28/2021
Sewanan LR, Park J, Rynkiewicz MJ, Racca AW, Papoutsidakis N, Schwan J, Jacoby DL, Moore JR, Lehman W, Qyang Y, Campbell SG. Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation. J Gen Physiol. 2021 09 06; 153(9). PMID: 34319370.
Read at: PubMed - Published on 12/11/2020
Racca AW, Rynkiewicz MJ, LaFave N, Ghosh A, Lehman W, Moore JR. M8R tropomyosin mutation disrupts actin binding and filament regulation: The beginning affects the middle and end. J Biol Chem. 2020 Dec 11; 295(50):17128-17137. PMID: 33453963.
Read at: PubMed - Published on 10/5/2020
Racca AW, Rynkiewicz MJ, LaFave N, Ghosh A, Lehman W, Moore JR. M8R tropomyosin mutation disrupts actin binding and filament regulation: The beginning affects the middle and end. J Biol Chem. 2020 12 11; 295(50):17128-17137. PMID: 33020181.
Read at: PubMed
View 53 more publications: View full profile at BUMC